Similar articles

• Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

  Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Roehrborn CG, et al. Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25. Urology. 2008. PMID: 18817961 Clinical Trial.
• Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

  Kaplan SA, Walmsley K, Te AE. Kaplan SA, et al. J Urol. 2005 Dec;174(6):2273-5. discussion 2275-6. doi: 10.1097/01.ju.0000181823.33224.a0. J Urol. 2005. PMID: 16280803
• Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.

  Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Kaplan SA, et al. BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x. Epub 2008 May 26. BJU Int. 2008. PMID: 18510659 Clinical Trial.
• Tolterodine for treatment of overactive bladder.

  Kanofsky JA, Nitti VW. Kanofsky JA, et al. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.
• [Treatment of the overactive bladder with detrusitol].

  Golomb J. Golomb J. Harefuah. 2000 Dec;139(11-12):467-70. Harefuah. 2000. PMID: 11341197 Review. Hebrew. No abstract available.